Diffuse Large B-cell Lymphoma (DLBCL) Market

Aug 28, 2020

20 likes | 53 Views

The total incident cases of Diffuse Large B-cell Lymphoma in 7MM was 67,743 in 2017. The incident population of DLBCL in the United States was 28,659, while Germany and Japan had 7,443 and 9,485 incident populations respectively in 2017. The market Size of DLBCL in the seven major markets was USD 2,692 million in 2017. Rising Incidence among Aging population, increase in R&D and CAR-T therapies approvals are some of the key factors expected to drive the DLBCL market forward in the coming years. The key players in the Diffuse Large B-cell Lymphoma market includes Bristol-Myers Squibb, Seattle Genetics, Takeda, ADC Therapeutics, Morphosys, Incyte, SymBio Pharmaceuticals, Denovo Biopharma, TG Therapeutics, Amgen, Bayer, Janssen, Pharmacyclics, Regeneron Pharmaceuticals, Celgene, Bristol Myers Squibb, Incyte Corporation, TCR2 Therapeutics, IMV, inc. & Merck, AstraZeneca, Autolus Therapeutics, Hoffmann-La Roche, Cellectar Bioscience, Debiopharm International and others. For more detailed information on Diffuse Large B-cell Lymphoma market, visit: https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market

DelveInsight

Download Presentation

Diffuse Large B-cell Lymphoma (DLBCL) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D